복막투석 환자의 빈혈 관리에 있어 에리스로포이에틴 자극제의 사용현황 및 비교평가
A Comparative Study on Trends and Efficacy of Erythropoietin Stimulating Agents in Patient Receiving Peritoneal Dialysis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: This was to evaluate the current usage of three erythropoietin stimulating agents (ESA) and their efficacy for management of anemia in peritoneal dialysis (PD) patients with chronic kidney disease. Methods: It was a retrospective comparative study through review of electronic medical records of chronic kidney disease patients undergoing PD at a tertiary teaching hospital from January 1998 to June 2013. Results: Average administration frequency was 1.66 times/week in EPO group, 0.75 times/week in DA group, and 0.19 times/week in MPG-EPO group. At the first 4 weeks, there were significant differences in mean hemoglobin levels between EPO and DA groups (9.25±1.28 g/dL, 10.02±0.95 g/dL each, p = 0.018) and also in hemoglobin response rates (10.0%, 45.2% each, p = 0.008), but since after 4 week, there had been no significant differences. There also showed no significant differences in achievement of hemoglobin target between the two groups. When converted to MPG-EPO in EPO/DA groups, there showed a slight increase in hemoglobin levels of both groups. MPG-EPO was the highest compared with two other drugs by the average cost based on the average weekly dose. Conclusion: EPO, DA, and MPG-EPO showed similar effects in treatment of anemia of PD patients based on hemoglobin target range (11.0~12.0 g/dL) which NFK-K/DOQI guidelines suggest. Though the average cost of MPG-EPO was higher than the other two drugs, the number of PD patients using MPGEPO has increased and it is thought that long half-life and low administration frequency of MPG-EPO have improved the compliance of PD patients who have to self-administrate.
Abstract
Objectives: This was to evaluate the current usage of three erythropoietin stimulating agents (ESA) and their efficacy for management of anemia in peritoneal dialysis (PD) patients with chronic kidney disease. Methods: It was a retrospective comparative study through review of electronic medical records of chronic kidney disease patients undergoing PD at a tertiary teaching hospital from January 1998 to June 2013. Results: Average administration frequency was 1.66 times/week in EPO group, 0.75 times/week in DA group, and 0.19 times/week in MPG-EPO group. At the first 4 weeks, there were significant differences in mean hemoglobin levels between EPO and DA groups (9.25±1.28 g/dL, 10.02±0.95 g/dL each, p = 0.018) and also in hemoglobin response rates (10.0%, 45.2% each, p = 0.008), but since after 4 week, there had been no significant differences. There also showed no significant differences in achievement of hemoglobin target between the two groups. When converted to MPG-EPO in EPO/DA groups, there showed a slight increase in hemoglobin levels of both groups. MPG-EPO was the highest compared with two other drugs by the average cost based on the average weekly dose. Conclusion: EPO, DA, and MPG-EPO showed similar effects in treatment of anemia of PD patients based on hemoglobin target range (11.0~12.0 g/dL) which NFK-K/DOQI guidelines suggest. Though the average cost of MPG-EPO was higher than the other two drugs, the number of PD patients using MPGEPO has increased and it is thought that long half-life and low administration frequency of MPG-EPO have improved the compliance of PD patients who have to self-administrate.
참고문헌 (27)
- 진동찬, "우리나라 말기신부전 환자의 투석현황", 대한의사협회지, 56(7), pp.562~568 (2013), 대한의사협회
- Chul Woo Yang, "Current status and future in patients with end stage renal disease in KOREA", 대한의사협회지, 56(7), pp.560~561 (2013), WPRIM
- Li S., "Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States", Kidney Int, 65(5), pp.1864~1869 (2004)
- Ohashi N., "Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease", Int J Nephrol Renovasc Dis, 5, pp.53~60 (2012)
- Ahn SC., "Anemia in patients with chronic renal failure on hemodialysis", Kidney Res Clin Pract, 13(4), pp.769~775 (1994)
- "KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease", Am J Kidney Dis, 47(5 suppl 3), pp.S11~S145 (2006)
- Shimosaka A., "Pharmacokinetics and Application of Erythropoietin Therapy : Overview of Epoetin Alfa Studies in Japan", Ann N Y Acad Sci, 718, pp.111~122 (1994)
- Horl WH., "Differentiating factors between erythropoiesis stimulating agents : an update to selection for anaemia of chronic kidney disease", Drugs, 73(2), pp.117~130 (2013)
- Padhi D., "An extended terminal halflife for darbepoetin alfa : results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis", Clin Pharmacokinet, 45(5), pp.503~510 (2006)
- Macdougall IC., "Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients", J Am Soc Nephrol, 10(11), pp.2392~2395 (1999)
- Locatelli F., "C. E. R. A. : pharmacodynamics, pharmacokinetics and efficacy in patients with chronic kidney disease", Expert Opin Investig Drugs, 16(10), pp.1649~1661 (2007)
- Curran MP., "Methoxy polyethylene glycolepoetin beta : A review of its use in the management of anaemia associated with chronic kidney disease", Drugs, 68(8), pp.1139~1156 (2008)
- Dougherty FC., "Continuous erythropoiesis receptor activator (CERA) provides dosedependent erythropoietic activity with a prolonged half-life in healthy volunteers", Ann Oncol, 15(suppl 3), pp.iii157~ (2004)
- Macdougall IC., "Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator(C. E. R. A. )in patients with chronic kidney disease", Clin J Am Soc Nephrol, 1, pp.1211~1215 (2006)
- Klinger AS, "KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD", Am J Kidney Dis (2013)
- Wazny LD., "Factors influencing erythropoietin compliance in peritoneal dialysis patients", Am J Kidney Dis, 40(3), pp.623~628 (2002)
- 이지영, "혈액 투석 환자에서 epoetin alfa와 darbepoetin alfa의 조혈 효과 비교: 무작위 교차 연구", Kidney Research and Clinical Practice, 28(5), pp.450~455 (2009), 대한신장학회
- Yoo SH., "Phase III clinical study of recombinant human erythropoietin(Eporon®)on anemia of chronic renal failure", Kidney Res Clin Pract, 19(6), pp.1053~1062 (2000)
- Product Information: MIRCERA(R) injection, "methoxy polyethylene glycol-eopetin beta injection" (2007), Hoffmann-La Roche,Inc
- Nissenson AR., "Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients", Am J Kidney Dis, 40(1), pp.110~118 (2002)
- Vanrenterghem Y., "Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients", Kidney Int, 62(6), pp.2167~2175 (2002)
- 신승희, "혈액투석 환자의 빈혈관리에서 Erythropoietin 반응에 영향을 미치는 인자", 한국임상약학회지, 21(2), pp.122~130 (2011), 한국임상약학회
- Klinger M., "Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis : a randomized trial", Am J Kideny Dis, 50(6), pp.989~1000 (2007)
- Carrera F., "Maintenance treatment of renal anemia in hemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly : a randomized comparative trial", Nephrol Dial Transplant, 25(12), pp.4009~4017 (2010)
- 박수경, "혈액투석 환자에서 적혈구생성자극제 사용과 헤모글로빈 변이성", Kidney Research and Clinical Practice, 30(1), pp.41~47 (2011), 대한신장학회
- Sikand H., "Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen", Ann Pharmacother, 42(1), pp.16~23 (2008)
- Jensen JD., "Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients", Eur J Clin Pharmacol, 50(3), pp.171~177 (1996)